Unknown

Dataset Information

Changes in complement C3a in the immunotherapy of advanced clear cell renal cell carcinoma.


ABSTRACT:

Background

Immunotherapy is an emerging treatment modality for clear cell renal cell carcinoma (CCRCC). As a molecule involved in the prognosis of CCRCC, the effect of complement C3a expression levels on immunotherapy is unclear. This study aims to investigate the correlation between C3a and clinicopathological features in early CCRCC, as well as the alterations in complement C3a during immunotherapy for advanced CCRCC and its influence on therapeutic outcomes.

Methods

Immunohistochemistry was used to detect the expression of complement C3a in newly diagnosed CCRCC tissues and paracancerous tissues. The peripheral serum of advanced CCRCC patients who underwent programmed cell death protein 1 (PD-1) antibody immunotherapy was collected before treatment and after four cycles o

SUBMITTER: Zhang C 

PROVIDER: S-EPMC11650347 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature